Sleep-disordered breathing in cystic fibrosis

Pediatr Pulmonol. 2021 Feb:56 Suppl 1:S23-S31. doi: 10.1002/ppul.25028.


Sleep-disordered breathing (SBD) is an under recognized comorbidity in the cystic fibrosis (CF) population across the lifespan. Nocturnal hypoxemia, obstructive sleep apnea, and nocturnal hypoventilation are respiratory abnormalities that occur commonly during sleep in patients with lung disease, and have deleterious consequences to the quality of life in people with CF. Effective screening for these abnormalities is needed to allow for timely initiation of treatment, which has been reported to be efficacious. Lack of treatment leads to worsened pulmonary, cardiovascular, and metabolic outcomes in patients. In this review, we give an overview of SBD for the CF clinician, including prevalence, treatment, and suggestions for future research. We strongly encourage the CF community to incorporate evaluation for SBD in CF clinical care so that outcomes for the subset of the CF patients with comorbid SBD improve.

Keywords: cystic fibrosis; lifespan; sleep-disordered breathing.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Child
  • Comorbidity
  • Cystic Fibrosis / complications*
  • Cystic Fibrosis / physiopathology
  • Humans
  • Hypoxia / complications
  • Oxygen Inhalation Therapy
  • Prevalence
  • Quality of Life
  • Sleep Apnea Syndromes / complications
  • Sleep Apnea Syndromes / diagnosis*
  • Sleep Apnea Syndromes / therapy